LAUSR

OBJECTIVE We aimed to investigate the prognostic values of systemic immune inflammation index and pan-immune inflammation value in patients with idiopathic low and moderate risk membranous nephropathy. PATIENTS AND METHODS All membranous nephropathy patients diagnosed in the nephrology clinic between January 2015 and January 2022 were reviewed retrospectively. Patients with idiopathic membranous nephropathy were included. The patients were divided into two groups; the complete remission group: whose proteinuria decreased below 0.3 g/day and serum albumin level above 3.5 g/dL after 6 months of conservative treatment, and the non-remission group: all other patients. Groups were compared in terms of systemic immune inflammation index and pan-immune inflammation value. RESULTS Patients in the non-remission group had significantly higher systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV) than patients in the complete remission group (p<0.05). An SII of 1,056.2 was found to have 63.6% sensitivity and 100% specificity in predicting non-remission, and a PIV of 447.4 was found to have 100% sensitivity and 70.6% specificity in predicting non-remission. CONCLUSIONS SII and PIV are reliable markers for predicting non-remission in patients with low and moderate risk idiopathic MN.